What is HC Wainwright’s Estimate for Korro Bio Q2 Earnings?

Korro Bio, Inc. (NASDAQ:KRRO) – Investment analysts at HC Wainwright cut their Q2 2026 earnings per share (EPS) estimates for Korro Bio in a research note issued on Thursday, January 29th. HC Wainwright analyst M. Kapoor now expects that the company will post earnings of ($1.85) per share for the quarter, down from their previous forecast of ($1.67). HC Wainwright has a “Neutral” rating on the stock. The consensus estimate for Korro Bio’s current full-year earnings is ($9.52) per share. HC Wainwright also issued estimates for Korro Bio’s Q3 2026 earnings at ($1.90) EPS, Q4 2026 earnings at ($1.95) EPS and FY2026 earnings at ($7.56) EPS.

Korro Bio (NASDAQ:KRRO) last issued its quarterly earnings data on Wednesday, November 12th. The company reported ($1.92) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.61) by $0.69. The company had revenue of $1.09 million for the quarter, compared to analyst estimates of $0.41 million. Korro Bio had a negative return on equity of 68.87% and a negative net margin of 1,199.53%.

KRRO has been the subject of a number of other research reports. Cantor Fitzgerald cut Korro Bio from an “overweight” rating to a “neutral” rating in a research report on Thursday, November 13th. Chardan Capital upgraded Korro Bio from a “neutral” rating to a “buy” rating and set a $15.00 price target for the company in a report on Thursday. Piper Sandler cut Korro Bio from an “overweight” rating to a “neutral” rating and set a $11.00 price target for the company. in a research note on Thursday, November 13th. Royal Bank Of Canada downgraded shares of Korro Bio from an “outperform” rating to a “sector perform” rating in a research report on Thursday, November 13th. Finally, William Blair reissued a “market perform” rating and issued a $10.00 target price on shares of Korro Bio in a research report on Wednesday. Two analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $66.50.

Korro Bio Price Performance

KRRO opened at $13.33 on Monday. The stock’s 50 day simple moving average is $8.29 and its 200 day simple moving average is $21.27. The stock has a market cap of $125.57 million, a P/E ratio of -1.42 and a beta of 2.99. Korro Bio has a 1-year low of $5.20 and a 1-year high of $55.89.

Institutional Trading of Korro Bio

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. JPMorgan Chase & Co. lifted its stake in Korro Bio by 6,185.5% in the third quarter. JPMorgan Chase & Co. now owns 199,249 shares of the company’s stock valued at $9,542,000 after acquiring an additional 196,079 shares during the last quarter. TCG Crossover Management LLC acquired a new stake in shares of Korro Bio in the third quarter valued at about $19,937,000. XTX Topco Ltd bought a new stake in shares of Korro Bio during the 3rd quarter valued at about $2,085,000. Polar Capital Holdings Plc increased its position in Korro Bio by 5.9% in the 3rd quarter. Polar Capital Holdings Plc now owns 264,694 shares of the company’s stock valued at $12,676,000 after buying an additional 14,694 shares in the last quarter. Finally, Millennium Management LLC lifted its position in Korro Bio by 1.8% in the 3rd quarter. Millennium Management LLC now owns 260,333 shares of the company’s stock valued at $12,467,000 after acquiring an additional 4,650 shares in the last quarter. 13.18% of the stock is currently owned by institutional investors and hedge funds.

Korro Bio Company Profile

Korro Bio, Inc is a clinical-stage biotechnology company focused on harnessing advanced protein engineering and synthetic biology to develop novel enzyme therapies and live microbial therapeutics. The company’s proprietary platform integrates directed evolution, high-throughput screening and computational design to optimize biological catalysts for a wide range of applications. By combining machine learning with experimental biology, Korro Bio seeks to accelerate the discovery and development of next-generation treatments for rare genetic disorders and complex metabolic diseases.

The company’s pipeline features both engineered enzyme therapeutics and live biotherapeutics.